Is Benzodiazepine Use Associated with the Risk of Dementia and Cognitive Impairment-Not Dementia in Older Persons? The Canadian Study of Health and Aging
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Background: The use of benzodiazepines in relation to cognitive decline remains an area of controversy in aging populations. Objective: This study aims to evaluate the risk of cognitive impairment–not dementia (CIND), Alzheimer disease (AD), and all-cause dementia with benzodiazepine use. The effect modification by sex was also investigated. Methods: Data come from the Canadian Study of Health and Aging, a 10-year multicentric study involving 10 263 participants randomly selected, 65 years and older, living in the community and in institutions. Current exposure to benzodiazepines was assessed in a face-to-face interview or self-reported in a questionnaire. Cox proportional hazard regression models, using age as time scale, were conducted to estimate hazard ratios, with adjustment for sex, education, smoking, alcohol intake, depression, physical activity, nonsteroidal anti-inflammatory drug use, and vascular comorbidities. Results: Data sets included 5281 participants for dementia as the outcome, 5015 for AD, and 4187 for CIND. Compared with nonusers, current use of benzodiazepines was associated with an increased risk of CIND (hazard ratio = 1.36; 95% CI = 1.08-1.72) in the simplest model. Results remained similar in the fully adjusted model (hazard ratio = 1.32; 95% CI = 1.04-1.68). There was no association between benzodiazepine use and the risk of dementia or AD. All these effects were similar between men and women. Conclusion and Relevance: Benzodiazepine use in older people from the general population is related to subsequent occurrence of cognitive dysfunction but not implicated in the pathogenesis of dementia or AD. Caution should be exercised when prescribing benzodiazepines to preserve global cognitive function.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There was no difference in the success rate of BZD discontinuation between the control and experimental groups in this case [72].”
From Benzodiazepines: Uses, Dangers, and Clinical Considerations (2021) · cites this paper as [72]
Citations
Cites
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
(1987) · PubMed · Cited by 2,657
The American Geriatrics Society 2012 Beers Criteria Update Expert Panel (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2012.03923.x · Cited by 2,578
Physical activity and risk of cognitive impairment and dementia in elderly persons
Laurin, D., Verreault, R., Lindsay, J., MacPherson, K., & Rockwood, K. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.498 · Cited by 1,561 · cited 1×
“Regular physical activity was categorized as none, low, moderate, and high.(24) Nonsteroidal antiinflammatory drugs (NSAIDs) were coded as user or nonuser.”
BackgroundSelf-citationBenzodiazepine Use in the United States
Olfson, M., King, M., & Schoenbaum, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1763 · Cited by 786
Benzodiazepine use and risk of Alzheimer's disease: case-control study
Billioti de Gage, S., Moride, Y., Ducruet, T., Kurth, T., Verdoux, H., Tournier, M., Pariente, A., & Begaud, B. (2014) · BMJ · doi:10.1136/bmj.g5205 · Cited by 558
Benzodiazepine use and risk of dementia: prospective population based study
Billioti de Gage, S., Begaud, B., Bazin, F., Verdoux, H., Dartigues, J.-F., Peres, K., Kurth, T., & Pariente, A. (2012) · BMJ · doi:10.1136/bmj.e6231 · Cited by 436
Martin, P., Tamblyn, R., Benedetti, A., Ahmed, S., & Tannenbaum, C. (2018) · JAMA · doi:10.1001/jama.2018.16131 · Cited by 401 · cited 1×
“Successful deprescribing interventions for benzodiazepines in older persons have recently been reported.(35,36)”
BackgroundPaterniti, S., Dufouil, C., & Alpérovitch, A. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200206000-00009 · Cited by 313
Gray, S. L., Dublin, S., Yu, O., Walker, R., Anderson, M., Hubbard, R. A., Crane, P. K., & Larson, E. B. (2016) · BMJ · doi:10.1136/bmj.i90 · Cited by 233 · cited 1×
“performance among benzodiazepine users.(5,8,13-16) Most of these studies assessed cognitive function on the basis of scores obtained with the use of global screening instruments and neuropsychological test batteries.”
Background
Research works printed but not linked: 4
- 10.1002/ana22362 · doi:10.1002/ana22362
- Teng EL, 1987, J Clin Psychiatry, 48, 314
- WHO Collaborating Centre for Drug Statistics Methodology, 2015, Guidelines for ATC Classification and DDD Assignment 2016
- Hogan DB, 2003, Can J Clin Pharmacol, 10, 72
Cited by
Benzodiazepines: Uses, Dangers, and Clinical Considerations
Edinoff, A. N., Nix, C. A., Hollier, J., Sagrera, C. E., Delacroix, B. M., Abubakar, T., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2021) · Neurology International · doi:10.3390/neurolint13040059 · Cited by 340
Promoting Successful Cognitive Aging: A Ten-Year Update
Krivanek, T. J., Gale, S. A., McFeeley, B. M., Nicastri, C. M., & Daffner, K. R. (2021) · Journal of Alzheimer’s Disease · doi:10.3233/jad-201462 · Cited by 172
Ma, T., Wang, Z., Qin, X. S., Ju, C., Lau, W. C. Y., Man, K. K. C., Castle, D. J., Chang, W. C., Chan, A. Y. L., Cheung, E. C. L., et al. (2023) · SLEEP · doi:10.1093/sleep/zsad124 · Cited by 82
“M Moreover, increased risks of some adverse outcomes, including cognitive decline 22,23 , Alzheimer’s disease 24 and injury 25,26 were found in older adults with a history of BZDs and Z-drugs use. a Based on existing evidence, a consensus was found that the consumption of BZDs and Z-drugs increased…”
Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia
Cacabelos, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093059 · Cited by 66
Anesthetic Considerations for Patients on Psychotropic Drug Therapies
Harbell, M. W., Dumitrascu, C., Bettini, L. M., Yu, S., Thiele, C. M., & Koyyalamudi, V. (2021) · Neurology International · doi:10.3390/neurolint13040062 · Cited by 64
“Given the high risk of cognitive impairment with benzodiazepine use in the elderly, its use should be avoided in those individuals older than 65 years of age [60].”
Background
Metadata
- Authors
- Nafti, M., Sirois, C., Kröger, E., Carmichael, P.-H., & Laurin, D.
- Affiliations
- Université Laval (CA)
- Centre de recherche du CHU de Québec-Université Laval (CA)
- Corresponding author
- Laurin, Danielle
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2019-10-09
- Volume
- 54
- Issue
- 3
- Pages
- 219-225
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2979645617
- Cited by
- 73
- References
- 32
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 12 · 2023: 16 · 2022: 8 · 2021: 12 · 2020: 6 · 2019: 1
- FWCI
- 5.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Annals of Pharmacotherapy (publishedVersion)
- PubMed (publishedVersion)
- Corpus Université Laval (Université Laval) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Intensive Care Unit Cognitive Disorders
- Keywords
- benzodiazepines, cognitive impairment without dementia, dementia, Alzheimer's disease, cognitive decline, older adults, sex differences, drug safety
- MeSH terms
- Aged, Aged, 80 and over, Aging, Alzheimer Disease, Benzodiazepines, Canada, Cognition, Dementia, Female, Humans, Male, Surveys and Questionnaires, Risk Factors, Sex Characteristics, Comorbidity, Proportional Hazards Models, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is Benzodiazepine Use Associated with the Risk of Dementia and Cognitive Impairment-Not Dementia in Older Persons? The Canadian Study of Health and Aging. https://app.cochat.ai/papers/10.1177/1060028019882037
- The paper
- Nafti, M., Sirois, C., Kröger, E., Carmichael, P.-H., & Laurin, D. (2020). Is Benzodiazepine Use Associated with the Risk of Dementia and Cognitive Impairment-Not Dementia in Older Persons? The Canadian Study of Health and Aging. Annals of Pharmacotherapy. https://doi.org/10.1177/1060028019882037
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.